NYLIM
TVRD

New York Life Investment Management’s Tvardi Therapeutics TVRD Stock Holding History

New York Life Investment Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,297
Closed -$501K – 1416
2022
Q4 		$501K Buy
1,297
+146
+13% +$55.5K 0.01% 931
2022
Q3 		$388K Buy
1,151
+85
+8% +$30.8K ﹤0.01% 969
2022
Q2 		$350K Buy
+1,066
New +$374K ﹤0.01% 1088

Other funds holding TVRD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

New York Life Investment Management's TVRD Position: Q1 2023 in Review

New York Life Investment Management sold out of Tvardi Therapeutics (TVRD) in Q1 2023, closing a stake of 1,297 shares — an estimated $501K sold.

New York Life Investment Management first reported a position in TVRD in Q2 2022 and held it in 3 quarters. The position peaked at $501K in Q4 2022. 163 funds tracked by Wall St. Rank hold TVRD as of Q1 2023.

  • New York Life Investment Management reported no remaining Tvardi Therapeutics position as of Q1 2023 after selling out during the quarter.
  • New York Life Investment Management sold 1,297 Tvardi Therapeutics shares in Q1 2023, an estimated $501K.
  • New York Life Investment Management first reported a position in Tvardi Therapeutics in Q2 2022 and held it in 3 quarters.
  • New York Life Investment Management's Tvardi Therapeutics position peaked at $501K in Q4 2022.
  • 163 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2023.

Based on New York Life Investment Management's 13F filing for Q1 2023, filed 8 May 2023.